Does Guideline-Directed Medical Therapy for Heart Failure Offer Benefits after LVAD Placement? - A Call for a Randomized Clinical Trial

Clyde W. Yancy; Gregg C. Fonarow; Adrian F. Hernandez

doi:10.1001/jamacardio.2019.5019

Does Guideline-Directed Medical Therapy for Heart Failure Offer Benefits after LVAD Placement? - A Call for a Randomized Clinical Trial

Clyde W. Yancy, Gregg C. Fonarow, Adrian F. Hernandez^*

^*Corresponding author for this work

Medicine, Cardiology Division

Research output: Contribution to journal › Comment/debate › peer-review

1 Scopus citations

Original language	English (US)
Pages (from-to)	183
Number of pages	1
Journal	JAMA cardiology
Volume	5
Issue number	2
DOIs	https://doi.org/10.1001/jamacardio.2019.5019
State	Published - Feb 2020

ASJC Scopus subject areas

Cardiology and Cardiovascular Medicine

Access to Document

10.1001/jamacardio.2019.5019

Cite this

@article{04fb762888054a639c06841b6d88ee30,

title = "Does Guideline-Directed Medical Therapy for Heart Failure Offer Benefits after LVAD Placement? - A Call for a Randomized Clinical Trial",

author = "Yancy, {Clyde W.} and Fonarow, {Gregg C.} and Hernandez, {Adrian F.}",

note = "Funding Information: spousal employment with Abbott Laboratories. Dr Fonarow reported personal fees from Abbott, Amgen, Bayer, CHF Solutions, Janssen, Medtronic, Merck, Novartis; grants from the National Institutes of Health outside the submitted work; and serves as an associate editor for JAMA Cardiology. Dr Hernandez reported grants and personal fees from AstraZeneca, Merck, and Novartis; personal fees from Bayer and Boston Scientific; and grants from Verily outside the submitted work. Funding Information: Neurohormonal Blockade and Clinical Outcomes in Patients With Heart Failure Supported by Left Ventricular Assist Devices",

year = "2020",

month = feb,

doi = "10.1001/jamacardio.2019.5019",

language = "English (US)",

volume = "5",

pages = "183",

journal = "JAMA Cardiology",

issn = "2380-6583",

publisher = "American Medical Association",

number = "2",

}

TY - JOUR

T1 - Does Guideline-Directed Medical Therapy for Heart Failure Offer Benefits after LVAD Placement? - A Call for a Randomized Clinical Trial

AU - Yancy, Clyde W.

AU - Fonarow, Gregg C.

AU - Hernandez, Adrian F.

N1 - Funding Information: spousal employment with Abbott Laboratories. Dr Fonarow reported personal fees from Abbott, Amgen, Bayer, CHF Solutions, Janssen, Medtronic, Merck, Novartis; grants from the National Institutes of Health outside the submitted work; and serves as an associate editor for JAMA Cardiology. Dr Hernandez reported grants and personal fees from AstraZeneca, Merck, and Novartis; personal fees from Bayer and Boston Scientific; and grants from Verily outside the submitted work. Funding Information: Neurohormonal Blockade and Clinical Outcomes in Patients With Heart Failure Supported by Left Ventricular Assist Devices

PY - 2020/2

Y1 - 2020/2

UR - http://www.scopus.com/inward/record.url?scp=85075252442&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85075252442&partnerID=8YFLogxK

U2 - 10.1001/jamacardio.2019.5019

DO - 10.1001/jamacardio.2019.5019

M3 - Comment/debate

C2 - 31738365

AN - SCOPUS:85075252442

VL - 5

SP - 183

JO - JAMA Cardiology

JF - JAMA Cardiology

SN - 2380-6583

IS - 2

ER -

Does Guideline-Directed Medical Therapy for Heart Failure Offer Benefits after LVAD Placement? - A Call for a Randomized Clinical Trial

ASJC Scopus subject areas

Access to Document

Other files and links

Cite this